National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedChing JH, Owens DK, Trafton JA
Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
This study used simulation of a Veterans Health Administration cohort to identify the opioid use disorder (OUD) treatment durations necessary for the elevated mortality risks during treatment transitions balanced by reductions in mortality while receiving medication-assisted treatment (MAT) with methadone or buprenorphine. A simulated cohort of 10,000 individuals with OUD was created by using parameters obtained through calibration and published meta-analyses of studies from North America, Europe, and Australia. Methadone treatment for 4 months or longer or buprenorphine for 2 months or longer resulted in 54 and 65 fewer deaths relative to not receiving MAT for the same duration. The authors estimated shorter treatment durations necessary to achieve net mortality benefits of 2 months or longer for methadone and 1 month or longer for buprenorphine. Necessary treatment increased more with smaller mortality reductions on treatment with larger relative risks during treatment transitions.
AHRQ-funded; HS027935; HS026128.
Citation: Ching JH, Owens DK, Trafton JA .
Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Addiction 2021 Dec;116(12):3494-503. doi: 10.1111/add.15574.
AHRQ-funded; HS027935; HS026128..
AHRQ-funded; HS027935; HS026128..
Keywords: Opioids, Substance Abuse, Behavioral Health, Mortality
Griffith KN, Feyman Y, Auty SG
Implications of county-level variation in U.S. opioid distribution.
Investigators used a novel dataset to investigate the distributional patterns of prescription opioids; whether opioid pill volume was associated with opioid-related mortality; and whether early state Medicaid expansions were associated with either pill volume or opioid-related mortality. Data on opioid shipments to retail pharmacies for 2006-2013 were obtained from the U.S. Drug Enforcement Administration and were mapped to opioid-related deaths (ORDs) from the CDC. The authors compared characteristics of counties in the highest and lowest quartiles for per capita pill volume (PCPV) to determine if they were associated with ORDs and whether early state Medicaid expansions were associated with either outcome. There were large geographic variations found in opioid distribution driven by differences in demographics, healthcare access, and healthcare supply. Early Medicaid expansion states were found to have reduced opioid pill volume. A one-pill increase in PCPV was associated with a 0.20 increase in ORDs per 100,000 population.
AHRQ-funded; HS026395.
Citation: Griffith KN, Feyman Y, Auty SG .
Implications of county-level variation in U.S. opioid distribution.
Drug Alcohol Depend 2021 Feb 1;219:108501. doi: 10.1016/j.drugalcdep.2020.108501..
Keywords: Opioids, Medication, Substance Abuse, Mortality